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Abstract 
Background: The essential amino acid tryptophan is catabolised mainly through the kynurenine pathway. Altered 
circulating levels of kynurenines have been reported in chronic inflammatory conditions and in several neuropsychi‑
atric disorders, including depression and schizophrenia. Candidate gene studies suggest that genes related to the 
kynurenine catabolism may be associated with attention‑deficit hyperactivity disorder (ADHD). Additionally, ADHD 
patients often report comorbid depression or anxiety. In this study we investigated serum levels of kynurenines in 
Norwegian adult ADHD patients and adult controls.
Methods: We compared serum levels of tryptophan and the seven tryptophan metabolites kynurenine, kynurenic 
acid, anthranilic acid, 3‑hydroxykynurenine, xanthurenic acid, 3‑hydroxyanthranilic acid and quinolinic acid in 133 
adult patients with ADHD and 131 adult controls (18–40 years). Riboflavin (vitamin B2), total vitamin B6 and the nico‑
tine metabolite cotinine were also measured. Serum samples were analysed using mass spectrometry. Patients and 
controls reported comorbid disorders and past (childhood) and current ADHD symptoms using the Wender Utah Rat‑
ing Scale (WURS) and the Adult ADHD Self‑report Scale (ASRS). Logistic regression was used to calculate odds ratios 
for having an ADHD diagnosis for different serum levels of each metabolite. In addition, we used Spearman’s correla‑
tion analysis to investigate the correlation between serum levels of tryptophan and kynurenines and ADHD symptom 
scores.
Results: Lower serum concentrations of tryptophan [odds ratio 0.61 (95 % confidence interval 0.45–0.83)], kynurenic 
acid [0.73 (0.53–0.99)], xanthurenic acid [0.65 (0.48–0.89)] and 3‑hydroxyanthranilic acid [0.63 (0.46–0.85)], and higher 
levels of cotinine [7.17 (4.37–12.58)], were significantly associated with ADHD. After adjusting for tryptophan levels, 
only 3‑hydroxyanthranilic acid and cotinine remained significant. Lower levels of tryptophan and kynurenine were 
also found to be correlated with higher total ASRS score and higher total WURS score, when adjusting for smoking 
and age.
Conclusions: Our results suggest that there may be differences in serum levels of tryptophan and kynurenines 
between adult ADHD patients and adult controls. Although our findings do not suggest a chronic immune activation 
in ADHD, the underlying mechanisms and possible clinical implications of the differences should be further explored.
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Background
Attention-deficit hyperactivity disorder (ADHD) is a 
neurodevelopmental disorder characterised by inat-
tention, hyperactivity and impulsivity and has a pooled 
prevalence rate of about 2.5 % in the adult population [1]. 
The symptoms are often severe and may cause serious 
difficulties in the daily life of affected individuals [2]. The 
disorder often coexists with other neuropsychiatric dis-
orders like depression and bipolar disorder, with which it 
also shares symptoms [3, 4]. The aetiology of ADHD is 
complex and is most likely explained by the combined 
impact of many environmental and genetic factors [5, 
6]. In a recent study on ADHD and its relation to low 
birth weight, it was suggested that genetic variants in the 
kynurenine pathway might contribute to ADHD symp-
tom severity [7].
The kynurenine pathway (Fig. 1) constitutes the major 
route for catabolism of the essential amino acid trypto-
phan [8]. More than 90 % of tryptophan is catabolised to 
kynurenine, mainly in the liver by the tryptophan spe-
cific enzyme tryptophan 2,3-dioxygenase (TDO), but 
also in lungs, kidneys, spleen, placenta and blood by the 
enzyme indole 2,3-dioxygenase (IDO) [9]. In the brain, 
the catabolism of tryptophan to kynurenine is driven by 
TDO and IDO located in astrocytes and microglia [9]. 
The activity of TDO depends on the concentration of 
tryptophan and is stimulated by high levels of cortisol, 
while IDO activity is enhanced mainly by pro-inflamma-
tory cytokines, such as interferon-γ, and reduced by the 
anti-inflammatory cytokine interleukin 4 [9]. Kynurenine 
is further converted into kynurenic acid (KA), by kynure-
nine aminotransferase (KAT I, II, III), or by kynurenine-
3-monooxygenase (KMO) into 3-hydroxykynurenine 
(HK), which is metabolised to 3-hydroxyantranilic acid 
(HAA) and eventually quinolinic acid (QA) [9]. These 
steps through the kynurenine pathway are dependent on 
the coenzymes pyridoxal 5′-phophat (PLP), the active 
form of vitamin B6 [8, 10], and flavin adenine dinucleo-
tide (FAD), the active form of riboflavin (vitamin B2) 
[10]. Thus, diet may influence tryptophan metabolism 
either directly or via vitamin levels. Moreover, serum lev-
els of tryptophan and vitamin B2 and B6 may be affected 
by smoking [11, 12].
KA and QA have neuroactive properties and exert 
multiple effects in the central nervous system. KA is an 
antagonist of the glutamatergic NMDA receptor and 
the cholinergic nicotinic α7-receptor and as such an 
endogenous protector against excitotoxicity [9]. High 
cerebrospinal fluid (CSF) levels of KA have been associ-


































Fig. 1 The kynurenine pathway of tryptophan catabolism. INF-γ interferon gamma, TDO tryptophan 2,3‑dioxygenase, IDO indole 2,3‑dioxygenase, 
KYNU kynureninase, KAT kynurenine aminotransferase, KMO Kynurenine mono‑oxygenase, PLP pyridoxal 5′‑phosphate (vitamin B6), FAD flavin 
adenine dinucleotide (vitamin B2), NAD nicotinamide adenine dinucleotide
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in humans, including patients with schizophrenia [14, 
15]. Reduced plasma levels of KA have been reported in 
depression [16] and in patients with bipolar disorder [17]. 
QA is an agonist of the NMDA receptor and may cause 
excitotoxicity [18]. High levels of QA have been found in 
several neurodegenerative diseases such as Huntington’s 
disease and Alzheimer’s disease [18].
ADHD often coexists with other neuropsychiatric dis-
orders that have been associated with altered levels of 
metabolites of the kynurenine pathway, such as major 
depression and bipolar disorder [3, 4]. Furthermore, 
known environmental risk factors for ADHD, such as 
preeclampsia, postnatal infection and malnutrition, may 
involve abnormal tryptophan catabolism [19, 20]. Neu-
ropsychological deficits, for example in executive func-
tioning, are often found in ADHD [21], and are thought 
to be related to a hypofunctional dopamine system [22]. 
Tryptophan metabolites can modulate several neuro-
transmitter systems, including dopaminergic transmis-
sion [9]. Moreover, in addition to kynurenine, tryptophan 
is also the precursor of serotonin (5-hydroxy-tryptamine, 
5-HT), a neurotransmitter that has been suggested as an 
important agent in several neuropsychiatric disorders 
including ADHD [23].
In this study we sought to compare serum levels of 
kynurenines between adult ADHD patients (N  =  133) 
and adult controls (N = 131) and also across continuous 




ADHD patients and controls were recruited as part of 
the Norwegian study “ADHD in adults in Norway: from 
clinical characterization to molecular mechanisms”, initi-
ated at the University of Bergen in 2004. Most patients 
were recruited by responding to invitation letters sent to 
people listed in a Norwegian national registry of adult 
ADHD patients. Some patients were recruited directly 
from psychiatrists or outpatient clinics, as described 
earlier [24]. All patients had been previously diagnosed 
with ADHD using either DSM-IV [25] or ICD-10 [26]. 
The ICD-10 criteria were adapted to the DSM-IV crite-
ria by allowing the inattentive subtype as sufficient for 
the ADHD diagnosis, and by accepting the coexistence of 
other neuropsychiatric disorders as long as they appeared 
after the criteria of ADHD were fulfilled. For the present 
study, only participants from whom we had access to 
blood samples, who were between 18 and 40 years, were 
of Norwegian ancestry, and who volunteered to partici-
pate after receiving oral and written information about 
the project were included (N = 264). The patient group 
consisted of 133 adults (71 females, 62 males) and the 
control group consisted of 131 students (75 females, 56 
males) recruited locally at the University of Bergen.
Measures
The majority of blood samples were collected locally at 
the Haukeland University Hospital campus in Bergen. 
Some samples were also collected by primary care physi-
cians in Bergen and at other locations in Norway. Fasting 
was not required before blood sampling. Blood samples 
were collected in serum tubes with gel separator. Samples 
collected outside the hospital were transported by mail 
to the laboratory. During transport, samples were kept 
at ambient temperature. Immediately upon arrival at the 
laboratory serum was separated and stored at −80 °C. All 
samples were visually inspected and samples with signs 
of haemolysis or degradation were excluded (N = 2). To 
avoid batch effects, control and patient samples were 
analysed together. Every second sample was from either 
controls or patients. Tryptophan and the seven kynure-
nines, kynurenine, kynurenic acid (KA), anthranilic 
acid (AA), xanthurenic acid (XA), 3-hydroxykynurenine 
(HK), 3-hydroxyanthranilic acid (HAA) and quinolinic 
acid (QA), as well as riboflavin (vitamin B2), B6 vitamers 
pyridoxal (PL) and pyridoxal-5′-phosphate (PLP), and the 
nicotine metabolite cotinine [27], were measured using 
stable isotope dilution liquid chromatography-tandem 
mass spectrometry, as described [28]. All biochemical 
analyses were performed by Bevital AS (http://www.bevi-
tal.no), Bergen.
All participants completed questionnaires with infor-
mation on mental health, education, occupational sta-
tus, and lifetime psychiatric co-morbidity. The latter was 
assessed by questions like “Have you ever experienced 
significant anxiety and/or depression?” and “Have you 
ever had problems with alcohol?” [3]. For assessment of 
current ADHD symptoms, all participants filled in the 
18-item Adult ADHD Self-report Scale (ASRS) consist-
ing of 9 questions specific to symptoms of inattentive-
ness and 9 questions on symptoms of hyperactivity and 
impulsivity, all with a 0–4 point Likert scale of symptom 
severity (0 = never/seldom, 4 = very often) [29]. In addi-
tion the 25-item version of the Wender Utah Rating Scale 
(WURS) was used for retrospective assessment of ADHD 
symptoms in childhood, each question with a Likert scale 
of 0–4 indicating the severity of the symptom (0 = not at 
all/very slightly, 4 = very much) [30].
Statistical analyses
To explore the material, age and ADHD symptom scores 
in the patient and control group were compared using 
Student’s t test, while χ2 test were used for comparing the 
categorical variables sex, alcohol and drug abuse, comor-
bid disorders and subgroups of ADHD. Total vitamin 
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B6 level was calculated as the sum of PL and PLP [31]. 
Kynurenine/tryptophan ratio (KTR), a marker of immune 
activation, was calculated as the serum concentration of 
kynurenine divided by the concentration of tryptophan, 
multiplied with 1000. About 80  % of the biochemical 
variables were non-normally distributed, and levels in 
patients and controls were therefore investigated using 
Mann–Whitney U tests. Spearman’s correlations for 
biochemical variables, age and sex were used to further 
explore the data.
For use in logistic regression all biochemical variables 
were split in tertiles, except for cotinine which was divided 
in three categories corresponding to the serum level of 
cotinine in non-smokers (<80 nmol/l), moderate smokers 
(80–1000 nmol/l) and heavy smokers (>1000 nmol/l) [32]. 
These three-way categorisations were chosen to assess 
possible effects of low, medium and high levels of the bio-
chemical variables/smoking. Blood cotinine can also be 
derived from nicotine in smokeless tobacco/snuff tobacco. 
Although we could not discriminate between different 
sources of nicotine, we considered the contribution from 
smokeless tobacco to be small in our study. At the time of 
sample collection, regular smoking was much more com-
mon than smokeless tobacco consumption. Some users 
also combine several sources of tobacco/nicotine (https://
helsedirektoratet.no/english/tobacco-control). Logistic 
regression with patient status (ADHD yes/no) as outcome 
was performed for each biochemical variable in two mod-
els, one with sex as covariate and another adjusting for 
both sex and tryptophan. Odds ratio (OR) with 95 % con-
fidence interval (CI) for ADHD was calculated per tertile 
of each metabolite (per category in the case of cotinine).
There was a greater age span in the ADHD group than 
in the control group, and it is known that tryptophan 
levels may decrease with age. Logistic regressions were 
therefore performed with two age subgroups of ADHD 
patients as outcome for each biochemical variable with 
adjustment for sex. The first age group, 19–33  years 
(N  =  97), corresponded to the age span of the control 
group, while the second group contained the patients 
with no age-matched controls (34–40  years, N  =  36). 
Associations between biochemical variables and patients’ 
comorbid disorders, i.e. bipolar disorder and anxiety/
depression, were also investigated using logistic regres-
sions adjusted for sex. A last logistic regression analysis 
was performed to explore the effect of current treatment 
with central stimulants.
Partial correlation analyses (Spearman’s) were used to 
explore associations between ADHD symptom severity 
and levels of biochemical variables, while adjusting for 
smoking (cotinine level) and age. The analyses were per-
formed in all participants and for patients and controls 
separately.
Student’s t test, χ2 test, Mann–Whitney U test and 
regular Spearman’s correlation analysis were performed 
in Statistical Package for Social Sciences version 22 (IBM 
Corp., Armonk, New York) for Apple OSX. All regression 
models as well as partial Spearman’s correlation were 
performed using R (The R Project for Statistical Comput-
ing) for Apple OSX. All p values were two-sided, and sta-
tistical significance was defined at the 5 % level.
Ethics
All patients gave written informed consent and the pro-
tocol was approved by the Regional Committee for Medi-




There were 264 participants included in this study, 133 
adult ADHD patients and 131 adult controls. A com-
parison of clinical data is shown in Table  1. Women 
were slightly overrepresented in both groups (53 and 
57 %). The median age of the patient group was signifi-
cantly higher than that of the control group (28.0 ver-
sus 22.5  years). In the patient group, 65.1  % reported 
a lifetime history of significant anxiety or depression, 
while this was reported by only 3.8  % of the controls. 
Among the ADHD patients, 9.9  % also reported hav-
ing a comorbid bipolar disorder, compared to none in 
the control group. There was a significant difference in 
the number of smokers, with 66.2 % of the patients hav-
ing a serum cotinine level of >80 nmol/l, compared to 
only 12.2 % of the controls. As expected, median child-
hood ADHD symptom scores (WURS) and median 
present ADHD symptom scores (ASRS) were much 
higher in the patient group (60 and 47 versus 12 and 
22 in the control group). According to standard cut-offs 
for ASRS, 6.2  % of the controls screened positive for 
ADHD.
Among patients for whom we had information on 
medication status, 113 patients (out of 123, 92 %) had a 
history of central stimulant treatment. When the blood 
samples were collected, 91 patients (out of 114, 80 %) still 




All kynurenine metabolites were positively correlated 
to kynurenine levels [Spearman’s rho (r): 0.24–0.58] 
(Table 2). Tryptophan levels showed a moderate correla-
tion with KA, XA and HAA, (r: 0.34–0.41), and a weak 
correlation with HK and QA (r: 0.14, 0.18). KA, XA, HAA 
and QA showed positive correlation with both vitamin 
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B2 (r: 0.15–0.27) and total vitamin B6 (r: 0.18–0.24). All 
correlations were statistically significant (p < 0.05).
There was a significant inverse correlation between 
age and tryptophan in this material as a whole (r: −0.24) 
and in the patient group (r: −0.30) in particular. A posi-
tive, although non-significant, correlation between age 
and tryptophan was also found in the control group (r: 
0.10). There was a significant but weak inverse correlation 
between cotinine and tryptophan (r: −0.13), XA (r: −0.16), 
HAA (r: −0.20), riboflavin (r: −0.13) and total vitamin B6 
levels (r: −0.16) when including all participants.
Metabolite levels according to ADHD status
Mann–Whitney U test showed significantly lower serum 
concentrations in the ADHD group for tryptophan, KA, 
XA, HAA, vitamin B2 (riboflavin) and total vitamin B6 
(PL + PLP), as well as a significantly higher level of coti-
nine, compared with the control group (Table 1). Distri-
bution of raw biochemical variables in tertiles for patients 
and controls are shown in Fig.  2. OR with 95  % confi-
dence interval (CI) for ADHD was calculated per tertile/
category of each metabolite (Fig.  3; Table  3), using two 
models: one adjusted for sex, and one adjusted for sex 
Table 1 Clinical and biochemical data
Significance <0.001: ‘***’, <0.01: ‘**’, <0.05: ‘*’
a χ2 test
b Student’s T test
c Mann–Whitney U test
d Calculated based on serum cotinine levels: 80–1000 nmol/l: moderate smoker, >1000 nmol/l: heavy smoker
e Calculated based on ASRS scores: A score of 21 or higher on the nine questions on inattentiveness is indicative of inattentive type, while a score of 21 or higher on 




i Median (25–75 percentile)
ADHD N Control N p value
133 131
Female, N (%) 71 (53.4) 133 75 (57.3) 131 0.52a
Age (range 18–40), median (SD) 28.0 (6.5) 133 22.5 (2.8) 131 <0.001***b
Alcohol problems, N (%) 24 (19.2) 125 1 (0.8) 131 <0.001***a
Problems with illicit drugs, N (%) 34 (27.0) 126 0 (0.0) 131 <0.001***a
Serious anxiety and/or depression, N (%) 82 (65.1) 126 5 (3.8) 126 <0.001***a
Bipolar disorder, N (%) 12 (9.9) 121 0 (0.0) 131 <0.001***a
Moderate smokersd, N (%) 51 (38.3) 133 12 (9.2) 131 <0.001***a
Heavy smokersd, N (%) 27 (27.8) 133 4 (3.1) 131 <0.001***a
Total WURS (range 0–100), median (SD) 60.0 (16.9) 118 12.0 (10.4) 129 <0.001***b
Total ASRS (range 0–72), median (SD) 47.0 (11.6) 123 22.0 (7.7) 128 <0.001***b
Combined typee, N (%) 65 (52.8) 123 3 (2.3) 128 <0.001***a
Hyperactive typee, N (%) 3 (2.4) 123 1 (0.8) 128 0.32a
Inattentive typee, N (%) 31 (25.2) 123 4 (3.1) 128 <0.001***a
Tryptophanf, i 77.3 (68.1–92.3) 133 83.6 (76.6–94.0) 130 0.004**c
Kynureninef, i 1.51 (1.29–1.78) 133 1.57 (1.40–1.76) 130 0.15c
Kynurenine/tryptophan ratio (KTR)g, i 19.0 (16.5–21.6) 133 18.4 (16.7–20.8) 130 0.46c
3‑hydroxykynurenine (HK)h, i 31.8 (22.2–39.4) 131 30.6 (26.1–28.1) 130 0.43c
Kynurenic acid (KA)h, i 38.9 (30.9–52.2) 131 46.7 (34.0–57.5) 130 0.03*c
Xanthurenic acid (XA)h, i 14.2 (11.0–22.4) 131 18.9 (13.7–24.7) 130 0.004**c
Anthranilic acid (AA)h, i 19.4 (13.2–24.3) 131 17.6 (14.9–22.8) 130 0.52c
3‑hydroxyanthranilic acid (HAA)h, i 29.8 (20.0–40.1) 131 35.4 (29.2–46.5) 130 <0.001***c
Quinolinic acid (QA)h, i 303 (258–387) 131 306 (274–364) 130 0.76c
Riboflavin (Vit. B2)h, i 18.1 (12.7–25.9) 131 19.9 (16.1–28.3) 130 0.02*c
Total vitamin B6h, i 58.5 (41.8–83.9) 131 67.1 (49.0–88.4) 130 0.05*c
Cotinineh, i 678 (2.48–1088) 131 1.2 (0.55–6.06) 130 <0.001***c
Page 6 of 12Aarsland et al. Behav Brain Funct  (2015) 11:36 
and tryptophan. Adjusting for sex, lower levels of tryp-
tophan, KA, XA, HAA and vitamin B2 were associated 
with increased risk of having ADHD. In addition, higher 
levels of cotinine were strongly associated with ADHD. 
In the second model, adjusting for sex and tryptophan, 
only HAA, riboflavin and cotinine remained significant 
predictors of ADHD/control status, while KA and XA 
were no longer significant.
Metabolite levels in relation to age, comorbidity 
and medication
Logistic regression using two age groups of ADHD 
patients, i.e. 19–33  years and 34–40  years, as outcome 
were performed to investigate the effect of age. Lower lev-
els of tryptophan [OR: 0.58 (95 % CI 0.35–0.93, p value: 
0.03)] and XA [0.56 (0.22–0.91, 0.02)] as well as higher 
levels of riboflavin [2.13 (1.32–3.54, 0.003)] and higher 
KTR [1.65 (1.02–2.71, 0.04)] were significantly associated 
with the age 34–40 group (N = 36). When the age 19–33 
ADHD subgroup (N  =  97) was compared to the con-
trol group (18–33, N = 131), lower levels of tryptophan 
[0.71 (0.51–0.99, 0.05)], HAA [0.66 (0.47–0.91, 0.01)] and 
riboflavin [0.53 (0.37–0.75, <0.001)], and higher levels 
of cotinine [7.84 (4.63–14.22, <0.001)] were significantly 
associated with increased risk of having ADHD. No sig-
nificant differences in serum concentrations were found 
between ADHD patients with or without self-reported 
anxiety/depression (all p values >0.13) or bipolar disorder 
(all p values >0.09). Comparisons of levels of tryptophan 
metabolites between medicated and drug-naïve patients 
showed a trend towards lower levels of KA and HAA in 
non-medicated patients in preliminary analyses. How-
ever, logistic regression analyses did not yield any signifi-
cant differences. The number of patients currently using 
antidepressants was too small to allow for comparisons.
Metabolite levels according to symptom scores
Correlation analyses adjusted for cotinine and age 
showed significant inverse correlations between the 
serum concentration of tryptophan and kynurenine 
and the current and past ADHD symptom scores ASRS 
and WURS, when including all participants (N  =  264) 
(Table  4). Analyses on symptom scores in the ADHD 
group separately (N =  133) confirmed that lower levels 
Table 2 Unadjusted Spearman’s correlations
Significance: <0.05 ‘*’
Trp tryptophan, Kyn kynurenine, KTR kynurenine/tryptophan ratio, HK 3-hydroxykynurenine, KA kynurenic acid, XA xanthurenic acid, AA anthranilic acid, HAA 
3-hydroxyanthranilic acid, QA quinolinic acid, Cot cotinine
Trp Kyn KTR HK KA XA AA HAA QA Vit. B2 Vit. B6 Cot ADHD status
All (N = 264)
 Age −0.24* −0.05 0.13* −0.13* −0.13* −0.26* 0.09 −0.27* −0.10 −0.04 −0.23* 0.26* 0.47*
 Sex 0.19* 0.18* 0.01 −0.11 0.21* 0.01 0.08 −0.04 −0.03 −0.14* 0.11 0.15* 0.04
 Trp 0.49* −0.46* 0.14* 0.34* 0.41* 0.10 0.34* 0.18* 0.17* 0.32* −0.13* −0.18*
 Kyn 0.48* 0.39* 0.48* 0.24* 0.36* 0.32* 0.58* 0.16* 0.19* −0.04 −0.09
 Vit. B2 −0.06 0.02 0.15* 0.23* 0.11 0.15* 0.27* 0.32* −0.13* −0.14*
 Vit. B6 −0.12 −0.12 0.22* 0.20* 0.03 0.24* 0.19* −0.16* −0.12*
 Cotinine 0.05 −0.06 −0.08 −0.16* 0.02 −0.20* −0.03 0.52*
ADHD (N = 133)
 Age −0.30* −0.08 0.22* −0.26* −0.11 −0.31* 0.05 −0.27* −0.08 0.22* −0.16 −0.04
 Sex 0.15 0.14 0.03 −0.04 0.08 0.03 −0.02 0.09 −0.00 −0.18* 0.09 0.13
 Trp 0.55* −0.41* 0.21* 0.34* 0.48* 0.01 0.35* 0.32* 0.18* 0.40* −0.07
 Kyn 0.46* 0.45* 0.50* 0.29* 0.32* 0.39* 0.64* 0.17 0.21* 0.07
 Vit. B2 −0.03 −0.01 0.15 0.29* 0.10 0.15 0.30* 0.32* −0.13
 Vit. B6 −0.17 −0.01 0.28* 0.26* −0.03 0.28* 0.24* −0.27*
 Cotinine 0.08 0.03 −0.11 −0.19* −0.03 −0.08 −0.01
Control (N = 131)
 Age 0.10 0.10 −0.01 0.05 0.01 −0.03 0.10 −0.06 −0.10 −0.19* −0.24* 0.14
 Sex 0.28* 0.25* −0.03 −0.19* 0.36* −0.01 0.20* −0.11 −0.08 −0.06 0.16 0.20*
 Trp 0.41* −0.48* 0.04 0.31* 0.27* 0.24* 0.19* −0.02 0.13 0.21* 0.06
 Kyn 0.55* 0.31* 0.46* 0.17 0.42* 0.16 0.50* 0.10 0.13 0.05
 Vit. B2 −0.10 0.03 0.09 0.12 0.13 0.03 0.21* 0.33* 0.06
 Vit. B6 −0.06 −0.26* 0.14 0.11 0.12 0.14 0.11 0.14
 Cotinine −0.02 −0.11 0.17 0.03 0.09 −0.10 −0.03
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of tryptophan and total vitamin B6 were correlated with 
higher total ASRS score and higher score on the ASRS 
inattentive subscale (Table 4). Lower levels of tryptophan 
were also correlated with higher WURS score. In the 
control group (N = 131), there were no significant corre-
lations between tryptophan and ADHD symptom scores 
(Table 4).
Discussion
In this study of 133 adult patients with ADHD and 131 
adult controls, we found significantly lower concentra-
tions of tryptophan, KA, XA and HAA in the patient 
group (Table  3). These results are strengthened by the 
observed inverse correlations between levels of trypto-
phan and kynurenine and total scores on both ASRS and 
WURS adjusted for smoking and age (Table 4). Together, 
our findings suggest a connection between severity of 
ADHD symptoms and serum levels of tryptophan and 
tryptophan metabolites. Furthermore, significantly lower 
levels of riboflavin and higher levels of cotinine were 
found among the ADHD patients compared to the con-
trols (Table  3). The kynurenine/tryptophan ratio (KTR) 
was not significantly different between the two groups 
in any of the analyses, and did not show any correlation 
to ADHD symptom scores (Table  4). Thus, there is no 
strong indication of chronic immune activation in the 
ADHD patients.
Our results are different from an earlier, exploratory 
study on kynurenines in children with ADHD which 
reported higher serum levels of tryptophan and lower 
levels of HK in children with ADHD (N = 35) compared 
to controls (N = 28) [33–35]. We do not have any clear 
explanation for these different findings for tryptophan 
levels. If the inverse relation between age and trypto-
phan levels in the patient versus control groups in our 
sample is a true finding, we would expect to find differ-
ent results in tryptophan metabolite studies of children 
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ADHD
Control
Fig. 2 Distribution in tertiles of biochemical variables. Each pair of columns contains a third of the participants. All participants are included 
(N = 264). ADHD patients are strongly represented in the lower concentrations of several metabolites, including tryptophan, XA, HAA and riboflavin. 
Controls are in majority in the middle concentrations of all metabolites except for KA
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Fig. 3 Odds ratio for ADHD with 95 % confidence intervals. Cotinine is divided in three categories corresponding to the serum level in non‑smok‑
ers, smokers and heavy smokers. High levels of tryptophan, KA, XA, HAA and riboflavin were associated with lower odds ratio for ADHD. High levels 
of cotinine were associated with higher odds ratio for ADHD. Significance <0.001: ‘***’, <0.01: ‘**’, <0.05: ‘*’
Table 3 Logistic regression
Odds ratio of ADHD per tertile of variable. Cotinine is divided into three categories corresponding to the serum level in non-smokers, smokers and heavy smokers. All 
participants included: N = 264. Significance <0.001: ‘***’, <0.01: ‘**’, <0.05: ‘*’
Adjusted for sex Adjusted for sex and tryptophan
B p value Odds ratio (95 %  
confidence interval)
B p value Odds ratio (95 % 
confidence interval)
Tryptophan −0.50 0.002** 0.61 (0.45–0.83)
Kynurenine −0.23 0.14 0.80 (0.59–1.08) −0.04 0.80 0.96 (0.69–1.34)
Kyn/Trp‑ratio (KTR) 0.12 0.45 1.12 (0.83–1.51) −0.11 0.53 0.90 (0.64–1.25)
3‑hydroxykynurenine (HK) −0.01 0.70 0.94 (0.70–1.27) 0.01 0.94 1.01 (0.74–1.38)
Kynurenic acid (KA) −0.32 0.04* 0.73 (0.53–0.99) −0.21 0.21 0.81 (0.59–1.12) 
Xanthurenic acid (XA) −0.43 0.006** 0.65 (0.48–0.89) −0.30 0.07 0.74 (0.54–1.03)
Anthranilic acid (AA) −0.01 0.97 0.99 (0.74–1.34) 0.04 0.79 1.04 (0.77–1.42)
3‑hydroxyanthranilic acid (HAA) −0.47 0.003** 0.63 (0.46–0.85) −0.38 0.02* 0.69 (0.50–0.94)
Quinolinic acid (QA) −0.02 0.90 0.98 (0.73–1.32) 0.04 0.82 1.04 (0.76–1.41)
Riboflavin (vitamin B2) −0.39 0.01* 0.68 (0.50–0.92) −0.34 0.03* 0.71 (0.52–0.97)
Total vitamin B6 −0.17 0.26 0.84 (0.62–1.14) −0.09 0.55 0.91 (0.67–1.24)
Cotinine 1.97 <0.001*** 7.17 (4.37–12.58) 1.94 <0.001*** 6.96 (4.22–12.25)
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are still too small and few in number to allow for definite 
conclusions.
High levels of tryptophan have also been shown in 
urine from ADHD children along with low HAA/HK 
ratios which made the authors suggest that this was 
due to a low activity of B6-dependent enzymes [36]. We 
observed low levels of B6 in our patient group, though 
not significantly different from controls. Like the low lev-
els of tryptophan observed in our patients, low B6 con-
centrations could be a sign of poor nutritional status.
Levels of tryptophan and kynurenines
Tryptophan levels, age and IDO/TDO activity
Differences in tryptophan concentrations between 
ADHD patients and controls could be a result of an 
abnormal IDO/TDO activity with increased catabolism 
through the kynurenine pathway. Increased catabolism 
of tryptophan to kynurenine has been found in patients 
with depression [16, 37], schizophrenia [38, 39], women 
with postpartum depression [40] and women with 
preeclampsia [19]. Tryptophan has also been shown to 
decrease with age in response to increased immune activ-
ity [12]. Increased IDO and TDO activity may increase 
KTR and the level of kynurenines. However, we found no 
significant difference in KTR between patients and con-
trols (Table 3). Instead we observed positive correlations 
between concentration of tryptophan and kynurenine in 
both the patient and control groups, indicating a nor-
mal conversion of tryptophan to kynurenine (Table  2). 
Furthermore, the levels of kynurenines in the ADHD 
group were not elevated, but were either similar to those 
of the control group (Kyn, HK, AA and QA) or lower 
than in controls (KA, XA and HAA) (Tables 1, 3).
Age and tryptophan were inversely associated in the 
patient group, but not in the control group, which had 
a smaller age span (18–33  years). Because of the strong 
association between age and patient/control-status, 
we chose to compare two age subgroups of patients, 
19–33 years and 34–40 years, in order to control for the 
effect of age. Analyses showed that lower levels of trypto-
phan [OR: 0.58 (95 % CI 0.35–0.93, p value 0.03)] and XA 
[0.56 (0.22–0.91, 0.02)], and higher KTR [1.65 (1.02–2.71, 
0.04)], were associated with the age 34–40 subgroup. 
However, using ADHD-status as outcome when includ-
ing only controls and patients in the age 19–33 subgroup, 
there were still significantly lower levels of tryptophan 
[OR: 0.71 (95  % CI 0.51–0.99, p: 0.05)] and HAA [0.66 
(0.47–0.91, 0.01)] in patients. Furthermore, in the par-
tial correlation analysis, tryptophan and kynurenine were 
both inversely correlated to ADHD symptom scores, 
even when adjusting for the effect of smoking and age 
(Table  4). Thus, although there seems to be an associa-
tion between higher age, lower tryptophan and increased 
KTR, low level of tryptophan in the ADHD group can-
not be fully explained by higher IDO or TDO activity. It 
seems likely that the difference in tryptophan levels could 
be partially due to a relative tryptophan deficiency in the 
ADHD group compared to the control group.
Table 4 Spearman’s correlations for ADHD symptom scores and serum variables, adjusted for cotinine and age
The 18-item ASRS (Adult ADHD Self-report Scale) is used to assess current ADHD symptom burden, with nine questions specific to hyperactivity/impulsivity and 
nine questions specific to inattentiveness. WURS (Wender Utah Rating Scale) consists of 25 items for retrospective assessment of childhood ADHD symptom burden. 
Significance: <0.05 ‘*’
Trp tryptophan, Kyn kynurenine, KTR kynurenine/tryptophan ratio, HK 3-hydroxykynurenine, KA kynurenic acid, XA xanthurenic acid, AA anthranilic acid, HAA 
3-hydroxyanthranilic acid, QA quinolinic acid, Cot cotinine
Trp Kyn KTR HK KA XA AA HAA QA Vit. B2 Vit. B6
All
 N = 248 ASRS total score −0.15* −0.14* 0.04 0.04 −0.08 0.01 0.04 −0.05 −0.04 −0.13* −0.06
 N = 250 ASRS inattentive −0.15* −0.13* 0.06 0.02 −0.08 −0.01 0.06 −0.03 −0.01 −0.06 −0.03
 N = 251 ASRS hyperactive/impulsive −0.14* −0.16* 0.02 0.03 −0.09 0.01 0.02 −0.07 −0.07 −0.17* −0.05
 N = 243 WURS total score −0.18* −0.15* 0.03 −0.01 −0.14* −0.08 0.05 −0.08 −0.05 −0.09 −0.01
ADHD
 N = 121 ASRS total score −0.20* −0.16 0.07 0.11 −0.05 0.01 0.05 −0.01 −0.14 −0.17 −0.22*
 N = 122 ASRS inattentive −0.20* −0.16 0.08 0.11 −0.03 0.06 0.02 0.07 −0.08 −0.09 −0.19*
 N = 123 ASRS hyperactive/impulsive −0.17 −0.14 0.03 0.09 −0.03 −0.02 0.06 −0.05 −0.12 −0.17 −0.14
 N = 115 WURS total score −0.27* −0.13 0.13 −0.08 −0.18 −0.16 0.15 −0.09 −0.16 0.05 −0.04
Control
 N = 127 ASRS total score −0.05 −0.11 0.03 −0.11 −0.12 0.01 −0.05 −0.07 −0.10 −0.14 −0.04
 N = 128 ASRS inattentive 0.01 −0.02 0.03 −0.13 −0.10 −0.04 0.02 −0.01 −0.01 −0.07 0.03
 N = 128 ASRS hyperactive/impulsive −0.10 −0.19* −0.01 −0.09 −0.13 0.05 −0.12 −0.10 −0.17 −0.19* −0.08
 N = 128 WURS total score −0.14 −0.14 0.03 −0.07 −0.11 −0.07 −0.07 −0.06 −0.08 −0.11 −0.01
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Vitamin B2 and B6 levels
We found significantly lower levels of riboflavin (vita-
min B2) in the ADHD group, in addition to lower HAA 
and XA. Our findings confirm a previous study report-
ing a positive association of HAA and XA levels to con-
centrations of PLP and riboflavin [10]. Similarly, plasma 
levels of HK have been observed to be inversely associ-
ated with plasma PLP [41]. We found an inverse correla-
tion between ASRS score and total vitamin B6 level in the 
ADHD group, adjusted for smoking and age (Table  4). 
It could be that low levels of total vitamin B6 among 
patients cause accumulation of HK and decreased lev-
els of the other kynurenine metabolites [36, 42, 43]. This 
is supported by the fact that HAA was still significantly 
associated with ADHD status when adjusting for tryp-
tophan levels in logistic regression analyses (Table  3). 
Analyses with KA and XA as predictors also suggest a 
difference, though not significant (Table 3).
Smoking
The high number of smokers, 38.3  % moderate smok-
ers and 27.8 % heavy smokers, is an important and well-
known characteristic of the ADHD group. Tryptophan 
and kynurenines (except HK) have been found to be 
inversely associated with smoking [12], and associations 
have been observed between blood levels of the nicotine 
metabolite cotinine and KTR [44]. Serum levels of ribo-
flavin and PLP are also known to be decreased in smok-
ers [11]. With 66 % smokers, it is likely that the levels of 
kynurenines in the ADHD group are affected by smoking 
either directly or via decreased levels of B-vitamins. Still, 
we found no strong correlation between cotinine and 
tryptophan, KTR, kynurenines or vitamins in our mate-
rial when using Spearman’s correlation analyses (Table 2). 
Furthermore, there were significant inverse correlations 
between ADHD symptom scores and tryptophan and 
kynurenine even when adjusting for smoking and age 
(Table 4).
Strengths and limitations
Our study included a relatively large number of partici-
pants (N = 264) and many measured metabolites, includ-
ing riboflavin, total vitamin B6 and cotinine, which are 
important as they influence tryptophan catabolism. 
There are still no generally accepted objective measures 
or biomarkers available for diagnosing ADHD. ASRS 
and WURS are widely used tools for evaluation of pre-
sent and past ADHD symptoms. The inclusion of ADHD 
symptom scores, although self-reported, allowed us to 
analyse the relationship between ADHD and biochemical 
markers as continuous variables.
The limitations of our study include base-line dif-
ferences between the patient and the control groups 
regarding age, comorbid conditions and the proportion 
of smokers, the possible effect of central stimulants and 
uncertainty regarding the quality of some blood samples. 
In our analyses we have explored the possible effect of 
these factors.
We had no information on dietary habits or the rela-
tionship between food intake and time of blood collec-
tion. We are therefore unable to conclude regarding the 
effect of nutrition upon serum levels of vitamin B2, vita-
min B6 and tryptophan.
Comorbid conditions are common in ADHD patients, 
and some of these conditions, notably depression and 
bipolar disorder, have been linked to alterations in tryp-
tophan catabolism. While regression analysis did not 
show any differences between ADHD patients with or 
without anxiety/depression or between patients with or 
without bipolar disorder, we cannot rule out the possibil-
ity that comorbid conditions also could affect tryptophan 
catabolism.
Little is known about the effect of central stimulants on 
tryptophan catabolism. The small number of drug-naïve 
patients in our study did not allow any real comparison 
between medicated and non-medicated patients. The 
trend of lower levels of tryptophan metabolites in non-
medicated patients in our study is however in line with 
a previous exploratory study in children with ADHD, 
showing a potential normalising effect of methylpheni-
date on tryptophan levels [36]. If this represents a true 
effect, our results could be an underestimation of the dif-
ferences in tryptophan levels between ADHD patients 
and controls.
Some blood samples were shipped by mail, and we 
do not have access to detailed information about their 
transit time before they were stored at −80  °C. Storing 
serum samples in room temperature may increase the 
levels of AA and reduce HK and HAA within a few days 
[31]. Thus, we cannot rule out the possibility that the 
concentrations of these metabolites were also affected 
by pre-analytic effects. In contrast, the concentration of 
tryptophan has been shown to be stable [31].
Lastly, the results of statistical analyses of the differ-
ent compounds were not adjusted for multiple test-
ing. The main reason for this choice was that since the 
biochemical variables are non-independent (Fig.  1), 
correction for all regression analyses would be too con-
servative. Instead, if calculating Bonferroni correction by 
dividing the critical significance level by the number of 
group comparisons performed by logistic regression, i.e. 
0.05/7, the threshold of significant would be 0.007. In the 
main logistic regression analysis using patient/control-
status as outcome (Table 3) tryptophan (p = 0.002), XA 
(p = 0.006) and HAA (p = 0.003) would remain signifi-
cant when applying this correction. Likewise, controlling 
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for the false-discovery rate (FDR-correction) for the 12 
analyses in the main logistic regression model (Table 3) 
would also yield significant differences for tryptophan 
(p = 0.01), XA (p = 0.02), HAA (p = 0.01) and riboflavin 
(p = 0.03).
Summary and conclusion
We found lower levels of tryptophan, KA, XA and HAA 
in adult patients with ADHD compared to adult controls. 
The levels of kynurenines are dependent mainly on the 
concentration of tryptophan, the rate of conversion by 
the enzymes TDO and IDO, and the level of circulating 
riboflavin and PLP. High TDO and IDO activity does not 
seem to explain these results, since we observed a normal 
kynurenine/tryptophan ratio (KTR) and generally low 
levels of both tryptophan and kynurenines in the ADHD 
group. The patient group also had low levels of riboflavin 
(vitamin B2) and total vitamin B6 (PL + PLP), something 
that could affect the balance of kynurenines in favour of 
HK. The oxidative effect of smoking on circulating B vita-
mins may be the cause of low levels of riboflavin and total 
vitamin B6, and possibly also the low level of tryptophan. 
Still, the level of the nicotine metabolite cotinine was 
only weakly correlated with tryptophan, the kynurenines 
and the vitamins. Also, low levels of tryptophan were 
correlated with high ADHD symptom scores, even when 
adjusting for smoking and age. This was observed not 
only when all participants were included but also in the 
patient group alone. Thus, low levels of tryptophan, KA, 
XA and HAA seem to be best explained by a deficiency in 
tryptophan and in vitamin B2 and B6. We cannot, how-
ever, exclude that differences in age, smoking habits and 
comorbid disorders could contribute to the observed dif-
ferences in levels of tryptophan and kynurenines. Further 
independent and carefully controlled studies are needed 
to clarify the relationship of tryptophan catabolism and 
ADHD.
Difference in nutritional status is a possible explana-
tion of both low levels of tryptophan and B vitamins. 
As has been observed in other studies [2, 45], it may be 
that patients with high symptom scores have a more dis-
ordered lifestyle and possibly also a poorer nutritional 
status. There is now increasing interest in nutrition and 
possible effects on ADHD and related symptoms, and 
it has been shown that dietary interventions are able to 
reduce symptom burden in children with ADHD [46, 
47]. Signs of low activity in PLP dependent enzymes 
in ADHD patients suggest that pyridoxine treatment 
may have an effect [36]. It is possible that also trypto-
phan supplements could be beneficial for some patients 
with ADHD, but more studies on larger populations are 
needed to further investigate the relation between ADHD 
and tryptophan catabolism.
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